SCHEMBL31332897

SCHEMBL31332897

CCOC(=O)c1n[nH]nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
PDE4D Q08499 1/20 0.44
KDM4E B2RXH2 5/20 0.44
KDM5B Q9UGL1 1/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 1/20 0.41
XBP1 P17861 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TLR9 Q9NR96 1/20 0.41
GLP1R P43220 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28728827 0.86 PDE4D (0.52) L3MBTL1PDE4DKDM4EPOLBLMNA
SCHEMBL841773 0.81 PDE4D (0.52) L3MBTL1PDE4DKDM4EPOLBLMNA
SCHEMBL1412585 0.78 PDE4D (0.44) L3MBTL1PDE4DKDM4EPOLBLMNA
SCHEMBL18137696 0.75 KDM5B (0.50) L3MBTL1KDM4EKDM5BLMNAMAPT
SCHEMBL1412427 0.74 KDM4E (0.44) PDE4DKDM4EPOLBMAPTMEN1
SCHEMBL2846088 0.73 HCAR2 (0.59) L3MBTL1PDE4DKDM4EKDM5BPOLB
SCHEMBL983844 0.73 L3MBTL1 (0.48) L3MBTL1PDE4DKDM4EKDM5BPOLB
SCHEMBL9941259 0.73 KDM4E (0.50) L3MBTL1PDE4DKDM4EKDM5BPOLB
SCHEMBL1412595 0.73 KDM4E (0.43) L3MBTL1PDE4DKDM4EPOLBLMNA
SCHEMBL31728508 0.73 KDM4E (0.40) L3MBTL1PDE4DKDM4EPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 L3MBTL1 3146/4885PDE4D 2469/4885KDM4E 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.